UBS Upgrades Jazz Pharmaceuticals to Buy, Sets $307 Target
UBS has lifted Jazz Pharmaceuticals to Buy with a $307 price target, arguing that improving fundamentals and a stren...
Index level declines can reflect profit-taking, macro shocks, or sector rotations. This intro covers common indicators to read with context.
23,215 articlesUBS has lifted Jazz Pharmaceuticals to Buy with a $307 price target, arguing that improving fundamentals and a stren...
AI-driven capital spending is accelerating demand for etching and related fabrication equipment, spotlighting semicon...
The White House rolled back Biden-era refrigerant limits affecting grocery stores and HVAC equipment, saying it will ...
As markets swing and retirees seek simple cash flow, a two-ETF approach aims to produce about $1,400 monthly from a $...
A hidden wrinkle in Social Security planning could shake up your retirement budget. This article breaks down what to ...
Investing in metals companies can feel like chasing a treasure chest. This deep-dive explains the opportunities, the ...
A U.S. couple with $50,000 spread across eight sinking funds faces renewed questions from financial advisers about wh...
A new HMDA analysis reveals a wide gap between DPA-eligible borrowers and actual users, underscoring outreach and acc...
As COMPUTEX 2026 approaches, investors wonder if will NVIDIA stock rise. This guide breaks down the event's potential...
Two energy giants, two distinct revenue playbooks. This article unpacks how Vistra and Constellation Energy produce i...
When a growth stock slides after earnings, it can shake your confidence. This guide explains why oddity tech stock pl...
As Cognyte readies its Q1 2027 earnings report, investors want clarity on growth, margins, and cash flow. This guide ...